Johnson & Johnson: Johnson & Johnson's trial of therapy for psoriatic arthritis meets its endpoints
Johnson & Johnson has reported positive results from a Phase IIIb trial of Tremfya (guselkumab) for active psoriatic arthritis. The post Johnson & Johnson's trial of therapy for psoriatic arthritis meets its endpoints appeared first on Clinical Trials Arena.
Read full article »
Johnson & Johnson is a New Jersey-based firm that engages in research, manufacturing and sale of healthcare products including consumer, pharmaceutical and medical devices.
Read more